Ontology highlight
ABSTRACT:
SUBMITTER: Martinelli E
PROVIDER: S-EPMC5548975 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Martinelli E E Cardone C C Troiani T T Normanno N N Pisconti S S Sforza V V Bordonaro A R AR Rachiglio A M AM Lambiase M M Latiano T P TP Modoni G G Cordio S S Giuliani F F Biglietto M M Montesarchio V V Barone C C Tonini G G Cinieri S S Febbraro A A Rizzi D D De Vita F F Orditura M M Colucci G G Maiello E E Ciardiello F F Iaffaioli Vincenzo V Nasti Guglielmo G Nappi Anna A Botti Gerardo G Tatangelo F F Chicchinelli Nicoletta N Montrone Mirko M Sebastio Annamaria A Guarino Tiziana T Simone Gianni G Graziano Paolo P Chiarazzo Cinzia C Maggio GabrieleDi G Longhitano Laura L Manusia Mario M Cartenì Giacomo G Nappi Oscar O Micheli Pietro P Leo Luigi L Rossi Sabrina S Cassano Alessandra A Tommaselli Eugenio E Giordano Guido G Sponziello Francesco F Marino Antonella A Rinaldi Antonio A Romito Sante S Muda Andrea Onetti AO Lorusso Vito V Leo Silvana S Barni Sandro S Grimaldi Giuseppe G Aieta Michele M
ESMO open 20160101 6
<h4>Background</h4>In the cetuximab after progression in KRAS wild-type colorectal cancer patients (CAPRI) trial patients with metastatic colorectal cancer (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) and cetuximab in first line followed by 5-Fluorouracil, folinic acid, oxaliplatin (FOLFOX) with or without cetuximab until progression. Limited data are available on the efficacy and safety of anti-epidermal growth factor receptor (anti-EGFR) agents on elderly patients with ...[more]